Study S000082

Effect of Dulaglutide (LY2189265) on the Pharmacokinetics of Digoxin in Healthy Subjects

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT01436201
Study type: INTERVENTIONAL
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 24
Start: 2011-09
Primary completion: 2011-11
Lead sponsor: Eli Lilly and Company
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:Digoxin; BIOLOGICAL:Dulaglutide
Results posted: TRUE
Secondary identifiers: OTHER:H9X-MC-GBCR

Registered primary outcomes

Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) of Digoxin [Predose (Digoxin) and up to 24 hours postdose on Days 7, 10, and 17]
Pharmacokinetics: Maximum Observed Drug Concentration (Cmax) of Digoxin [Predose (Digoxin) and up to 24 hours postdose on Days 7, 10, and 17]
Pharmacokinetics: Time of Maximum Observed Drug Concentration (Tmax) of Digoxin [Predose (Digoxin) and up to 24 hours postdose on Days 7, 10, and 17]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0011520	No Dose Adjustment is Recommended for Digoxin, Warfarin, Atorvastatin or a Combination Oral Contraceptive When Coadministered with Dulaglutide. de la Peña A, Clinical pharmacokinetics	2017	Other trial	PMID 28357715 DOI	cites ClinicalTrials.gov:NCT01436201; registry reference DERIVED:28357715